Financials Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:00:39 2024-05-17 pm EDT			5-day change	1st Jan Change
5.615 ^USD	+0.63%		+11.51%	+33.18%

May. 15	Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results	MT
May. 15	Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	875.3	718.6	874.1	418.2	242.8	324.7	-	-
Enterprise Value (EV) ¹	875.3	718.6	874.1	418.2	242.8	135.8	389.8	687.8
P/E ratio	7.78 x	31.3 x	27.1 x	67.2 x	106 x	-93 x	-16.9 x	42.9 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	3.85 x	2.9 x	3.25 x	1.64 x	1.26 x	1.67 x	1.4 x	2.14 x
EV / Revenue	3.85 x	2.9 x	3.25 x	1.64 x	1.26 x	0.7 x	1.68 x	4.52 x
EV / EBITDA	22.4 x	-	19.4 x	-	-	-6.73 x	-10.5 x	57.8 x
EV / FCF	-	-	-	-	-	0.71 x	1.53 x	2.31 x
FCF Yield	-	-	-	-	-	140%	65.2%	43.3%
Price to Book	-	-	-	-	-	-	-	-
Nbr of stocks (in thousands)	53,337	54,692	55,712	56,590	57,532	58,198	-	-
Reference price ²	16.41	13.14	15.69	7.390	4.220	5.580	5.580	5.580
Announcement Date	2/25/20	2/10/21	2/23/22	2/8/23	2/7/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	227.2	248.2	268.7	254.4	192.6	194.5	232.4	152.1
EBITDA ¹	39.16	-	45.01	-	-	-20.2	-37.3	11.9
EBIT ¹	22.81	27.24	42.16	6.329	-13.95	-21.4	-38.5	10.7
Operating Margin	10.04%	10.98%	15.69%	2.49%	-7.24%	-11%	-16.57%	7.03%
Earnings before Tax (EBT) ¹	29.03	31.66	42.36	11.3	6.339	-1.9	-19.5	10.7
Net income ¹	115.6	23.34	33.15	6.275	2.509	-3.6	-19.5	8.5
Net margin	50.86%	9.4%	12.34%	2.47%	1.3%	-1.85%	-8.39%	5.59%
EPS ²	2.110	0.4200	0.5800	0.1100	0.0400	-0.0600	-0.3300	0.1300
Free Cash Flow ¹	-	-	-	-	-	190	254	298
FCF margin	-	-	-	-	-	97.69%	109.29%	195.92%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	2,504.2%
FCF Conversion (Net income)	-	-	-	-	-	-	-	3,505.88%
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	2/25/20	2/10/21	2/23/22	2/8/23	2/7/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q2	2023 Q3	2023 Q4
Net sales ¹	68.02	60.19	64.39	65.32	64.48	46.06	38.82	45.27
EBITDA	9.342	-	-	-	-	-	-	-
EBIT ¹	8.636	-7.669	3.461	3.908	6.629	-2.867	-5.995	-7.094
Operating Margin	12.7%	-12.74%	5.38%	5.98%	10.28%	-6.23%	-15.45%	-15.67%
Earnings before Tax (EBT) ¹	8.61	-7.564	3.79	5.461	9.613	2.592	-0.12	-1.661
Net income ¹	7.078	-6.43	2.574	3.27	6.861	1.52	0.137	-2.4
Net margin	10.41%	-10.68%	4%	5.01%	10.64%	3.3%	0.35%	-5.3%
EPS ²	0.1200	-0.1100	0.0500	0.0600	0.1200	0.0300	-	-0.0400
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	2/23/22	5/5/22	8/3/22	11/2/22	2/8/23	7/27/23	11/8/23	2/7/24

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	65.1	363
Net Cash position ¹	-	-	-	-	-	189	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-1.745 x	30.51 x
Free Cash Flow ¹	-	-	-	-	-	190	254	298
ROE (net income / shareholders' equity)	-	-	6.92%	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share	-	-	-	-	-	-	-	-
Cash Flow per Share	-	-	1.130	-	-	-	-	-
Capex ¹	-	-	-	-	-	1.3	1.4	1.4
Capex / Sales	-	-	-	-	-	0.67%	0.6%	0.92%
Announcement Date	2/25/20	2/10/21	2/23/22	2/8/23	2/7/24	-	-	-

¹USD in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Vanda Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.58 USD

Average target price

5.21 USD

Spread / Average Target

-6.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VANDA PHARMACEUTICALS INC.	+33.18%	325M
VERTEX PHARMACEUTICALS INCORPORATED	+8.71%	114B
REGENERON PHARMACEUTICALS, INC.	+11.27%	104B
BIONTECH SE	-12.73%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.07%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.01%	14.28B
SAREPTA THERAPEUTICS, INC.	+35.27%	12.55B

Bio Therapeutic Drugs